TScan Therapeutics, Inc.
TCRX
$1.09
$0.043.33%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 286.02% | 139.37% | 473.88% | 283.57% | -90.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 286.02% | 139.37% | 473.88% | 283.57% | -90.78% |
| Cost of Revenue | -37.18% | 20.66% | 21.42% | 19.84% | 31.01% |
| Gross Profit | 44.68% | -15.73% | -12.21% | -13.69% | -88.81% |
| SG&A Expenses | -25.39% | 6.28% | 17.01% | 21.90% | 30.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.65% | 17.50% | 20.43% | 20.29% | 30.84% |
| Operating Income | 40.46% | -13.58% | -13.31% | -15.55% | -71.90% |
| Income Before Tax | 35.83% | -19.48% | -16.71% | -13.22% | -82.58% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 35.83% | -19.48% | -16.71% | -13.22% | -82.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.83% | -19.48% | -16.71% | -13.22% | -82.58% |
| EBIT | 40.46% | -13.58% | -13.31% | -15.55% | -71.90% |
| EBITDA | 41.29% | -14.84% | -15.02% | -18.10% | -79.31% |
| EPS Basic | 72.04% | -12.33% | -8.88% | 4.15% | -54.30% |
| Normalized Basic EPS | 73.66% | -12.34% | -8.88% | 4.17% | -49.59% |
| EPS Diluted | 72.04% | -12.33% | -8.88% | 4.15% | -54.30% |
| Normalized Diluted EPS | 73.66% | -12.34% | -8.88% | 4.17% | -49.59% |
| Average Basic Shares Outstanding | 129.48% | 6.36% | 7.21% | 18.13% | 18.32% |
| Average Diluted Shares Outstanding | 129.48% | 6.36% | 7.21% | 18.13% | 18.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |